GET DAILY SIGNALSWhy Is ALX Oncology Holdings (ALXO) Stock Down -8.53% Today?
Key Takeaways
- Shares of ALXO fell 8.53% to roughly $1.18 on Tuesday, reversing most of the prior session's 11.26% surge.
- The primary driver was profit-taking and a sharp technical reversal, with no single company-specific negative headline behind the decline.
- Sentiment around the pre-revenue biotech remains fragile after recent financing-related dilution, including a February $150 million equity offering and an October pre-funded warrant exchange.
- A risk-off tone across small-cap biotechnology amplified the move as peers traded lower.
- Traders are now focused on upcoming third-quarter results and clinical pipeline updates.
- For more on this ticker's Price Targets, Earnings, and Forecast, visit Tickeron's dedicated pages.
- Explore Trending AI Robots to see which automated strategies are leading in current market conditions.
Opening Summary
ALX Oncology Holdings Inc. (ALXO), a South San Francisco-based clinical-stage immuno-oncology company developing cancer therapies led by its CD47-blocking candidate evorpacept and EGFR-targeted antibody-drug conjugate ALX2004, saw its stock fall 8.53% to approximately $1.18 on Tuesday, down from the prior session's closing price of $1.29. The decline unwound most of Monday's 11.26% rally, with markets attributing the move primarily to profit-taking and renewed risk-off sentiment in small-cap biotech rather than to any fresh company-specific announcement.
Profit-Taking After Monday's Surge
The sharpest driver of Tuesday's price action was a straightforward reversal of the prior session's momentum. ALXO surged 11.26% on Monday, and much of that gain evaporated within a single session as short-term traders locked in profits. For a thinly traded, pre-revenue clinical-stage company, such two-way volatility is not unusual: with a 52-week range spanning roughly $0.86 to $2.66 and a market capitalization of only about $160 million to $190 million, relatively modest order flow can produce outsized percentage swings in either direction.
Fragile Sentiment and Dilution Overhang
Underlying the reversal is a longer-running overhang tied to balance-sheet and financing concerns. ALXO has no approved products or product revenue, funding its operations through equity raises. In February 2026 the company completed a registered offering that generated roughly $150 million in gross proceeds, and an October 2026 pre-funded warrant exchange involving about 13.35 million shares contributed to a slide toward a multi-year low near $0.86. That dilution history has left investors sensitive to any signs of renewed selling pressure, making rallies prone to sharp givebacks.
Sector and Macro Backdrop
The decline also coincided with broader weakness across small-cap biotechnology. Risk-off sentiment in the sector, partly driven by macro uncertainty and a rotation away from high-beta, development-stage names, weighed on peers and removed the supportive backdrop that had helped fuel Monday's bounce. With no clinical data catalyst or regulatory headline in the session, ALXO was left to trade on technical and sentiment factors rather than fundamentals.
Market Context and Trading Activity
The stock remains well below its 50-day and 200-day moving averages, and Tuesday's slide kept it in the lower portion of its recent trading range. Volume has been choppy in recent sessions, consistent with a relatively thin float that amplifies percentage moves. The price action diverged from the broader large-cap indices, which did not experience a comparable sell-off, underscoring that the move was largely company- and small-cap-sector-specific rather than a broad-market event.
What Comes Next for ALXO
Looking ahead, the focus shifts to ALXO's upcoming third-quarter 2026 results, which analysts had projected for early-to-mid November. Investors will be watching cash runway, spending trends, and any updates on the company's clinical programs, including the Phase 2 ASPEN-09-Breast trial and the Phase 1 ALX2004 dose-escalation study. The company also announced participation in several November and December investor conferences, which could offer management an opportunity to address pipeline progress. Key risks include further dilution, clinical trial setbacks, and continued volatility in the small-cap biotech space.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of automated approaches to evaluate. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALXO's RSI Oscillator recovers from oversold territory
The RSI Indicator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 37 of the 43 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ALXO as a result. In 65 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for ALXO moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ALXO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Advertisement